DeepMind unveils AlphaGenome 2: Predicting disease effects in DNA
Google DeepMind has introduced AlphaGenome 2, an AI model that predicts how changes in DNA affect specific cell types and contribute to disease progression.
What happened?
Google DeepMind has unveiled AlphaGenome 2, an AI model designed to understand how cells interpret DNA sequences. The model predicts how genetic sequences and mutations affect specific human cell types and how these changes are linked to disease. The work addresses the complexity of the non-coding regions of the genome.
Key facts
| Modellnamn | AlphaGenome 2 |
|---|---|
| Utvecklare | Google DeepMind |
| Fokusområde | Dna-sekvenser, celltyper och sjukdomsmekanismer |
”Predicting how DNA sequences and their variations impact specific human cell types and disease.”
Why it matters
A large portion of human DNA consists of non-coding sequences whose regulatory functions have historically been difficult to map. By predicting how genetic variations alter gene expression in specific cells, new opportunities arise to identify the biological mechanisms behind complex diseases.
Who is affected?
Biomedical researchers, geneticists, and drug developers are directly affected by the tool for analysing disease mechanisms. In the long term, the results may impact healthcare through improved precision medicine.
Impact on the EU
The research is subject to current European data protection laws and ethical frameworks for biomedical research. Models and research results of this nature are expected to be made available to academic environments across the EU.
What else you should know
The model builds on DeepMind's previous work in biological AI, where AlphaFold previously mapped the three-dimensional structures of proteins.
Quick answers about this story
Vad har hänt?
När hände det?
Varför spelar det roll?
Vilka berörs av tekniken?
The link opens in a new window and leads to the publisher's own site.
Källan har spårats automatiskt från utgivaren via Aheadlines signalkedja.
Get similar news straight to your inbox
The reader's room
Send in a question or an addition. The newsroom reads everything before it's published and replies when relevant. No AI-generated text – just people.
Sign in to submit a comment or question.
Read the article through your role
- Decide whether this affects strategy over 6–12 months or is just noise.
- Discuss with leadership: do we own the right question or does ownership need to move?
- Ask: what risk are we taking by NOT acting on this this quarter?
Generated angle — not editorial analysis of "DeepMind unveils AlphaGenome 2: Predicting disease effects i"